Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female between 18 and 55 years old~* BCG group: Known to be BCG-vaccinated over 2 years before, PPD positive (range 6-15 mm or any documented value between 6-15 mm on medical file in the past), with no active, chronic or past TB disease as confirmed by chest X ray, negative QuantiFERON-TB Gold In Tube test and negative 6-day lymphocyte tests.~* Infection group: Known to be treated for latent TB, PPDpositive (equal or over 10 mm or documented equal or over 10 mm positive on medical file in the past), previously TB infected but with no active disease confirmed by chest X ray, may have received chemoprophylaxis but with no TB treatment/chemoprophylaxis within the preceding 2 years, positive QuantiFERON-TB Gold In Tube test and/or positive 6-day lymphocyte test.~* Healthy based on medical examination/history at the inclusion~* Signed informed consent~* Prepared to grant authorized persons access to the medical records~* The volunteer is likely to comply with instructions~Exclusion Criteria:~* Granulomatous disease (by chest X-ray)~* Vaccinated with live vaccine 3 months before first vaccination~* Administration of immune modulating drugs (steroids, immunosuppressive drugs or immunoglobulins) 3 months before the first vaccination~* HBV, HCV or HIV sero-positive~* Participation in other clinical trials~* Known hypersensitivity to any of the vaccine components~* Laboratory parameters outside of normal range judged by PI to be clinically relevant~* Pregnant women/planned pregnancy and/or breastfeeding within the trial period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Latent TB infection group (Type: EXPERIMENTAL): The latent TB group will receive two injections of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart.
- BCG vaccinated group (Type: EXPERIMENTAL): The BCG vaccinated group will receive two vaccinations of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart

Based on this trial design, predict the completion outcome and termination type (if applicable).